

AGENDA

FRIDAY 28 OCTOBER

08.30

08.45 Welcome and introductions

MJ Keating, University of Texas MD Anderson Cancer Center, Houston TX, USA

09.00

SESSION 1 – Molecular biology

09.30

Chaired by H Dohner, Universitätsklinikum Ulm, Ulm, Germany

09.00 Perspectives and state of the art

S Stilgenbauer, Universitätsklinikum Ulm, Ulm, Germany

10.00

09.30 Looking to the future with functional genomics

C Croce, The Ohio State University, Columbus, OH, USA

10.30

10.00 Selected oral presentations from submitted abstracts

10.40 Discussion

11.00

Coffee

11.30

SESSION 2 – Cellular biology

12.00

Chaired by F Caligaris-Cappio, Istituto Scientifico San Raffaele, Milan, Italy

11.30 The microenvironment

F Cymbalista, Hospital Avicenne, Bobigny, France

12.30

12.00 Clinical potential and 'logical synergies'

JA Burger, University of Texas MD Anderson Cancer Center, Houston TX, USA

13.00

12.30 Selected oral presentations from submitted abstracts

13.00 Discussion

13.30

Lunch

14.00

14.30

15.00

SESSION 3 – Prognostication

15.30

Chaired by N Kay, Mayo Clinic, Rochester, MD, USA

15.00 State of the art and perspectives

W Wierda, University of Texas MD Anderson Cancer Center, Houston TX, USA

16.00

15.30 Selected oral presentations from submitted abstracts

16.00 Discussion

16.30

16.45–18.00 POSTER VIEWING (Sessions 1, 2 and 3)

17.00

17.30

17.30–19.00 WELCOME RECEPTION

18.00

18.30

19.00

SATURDAY 29 OCTOBER

09.00

SESSION 4 – Treatment including SCT

Chaired by E Montserrat, Hospital Clinic, University of Barcelona, Barcelona, Spain

09.30

09.00 State of the art and perspectives

10.00

M Hallek, Universität zu Köln, Köln, Germany

09.30 Selected oral presentations from submitted abstracts

10.30

10.15 Discussion

11.00

Coffee

11.30

SESSION 4 Continued – Treatment including SCT

Chaired by E Montserrat, Hospital Clinic, University of Barcelona, Barcelona, Spain

12.00

11.30 Transplantation

D Maloney, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

12.30

12.00 Selected oral presentations from submitted abstracts

12.30 Discussion

13.00

13.30

Lunch

14.00

14.30

SESSION 5 – Novel treatment approaches

Chaired by J Gribben, St Bartholomew's and Royal London School of Medicine, London, UK

15.30

14.30 Pipeline overview and perspectives

J Byrd, The Ohio State University, Columbus, OH, USA

16.00

15.00 'Logical synergies'

T Kipps, University of California San Diego, San Diego, CA, USA

16.30

15.30 Selected oral presentations from submitted abstracts

16.15 Discussion

17.00

17.30

17.00–18.00 POSTER VIEWING (Sessions 4 and 5)

18.00

SUNDAY 30 OCTOBER

08.30

SESSION 6 – Optimizing trial design in CLL

09.00 *Chaired by S O'Brien, University of Texas MD Anderson Cancer Center, Houston TX, USA*

09.30 MRD and I7p-

P Hillmen, St James University Hospital, Leeds, UK

09.00 Future directions of clinical trials

J Gribben, St Bartholomew's and Royal London School of Medicine, London, UK

09.30 Mechanism based strategies

W Plunkett, University of Texas MD Anderson Cancer Center, Houston TX, USA

10.00 Discussion

11.00

Coffee

11.30

SESSION 7 – Perspectives from the iwCLL Scientific Committee

Chaired by MJ Keating, University of Texas MD Anderson Cancer Center, Houston TX, USA

12.00 11.30 Case studies highlighting key topics and discussions

S O'Brien, University of Texas MD Anderson Cancer Center, Houston TX, USA

11.50 Meeting highlights (including best poster award)

P Ghia, Università Vita-Salute San Raffaele, Milan, Italy

12.30 12.10 Review and discussion – iwCLL Scientific Committee

12.30 Next steps for the iwCLL – MJ Keating

13.00

Meeting close
